M. Huang

Evaluation of pathological complete response as a trial-level surrogate for long-term survival outcomes among triple-negative breast cancer patients receiving neoadjuvant therapy.

P. Fasching, V. Karantza, A. Haiderali, 2019, Annals of oncology : official journal of the European Society for Medical Oncology.

995P A pan-cancer analysis of KMT2D as a potential biomarker for immune checkpoint therapy

X. Guan, S. Cai, Xiaojun Wu, 2021, Annals of Oncology.

186P Evaluation of event-free survival as a surrogate for overall survival in early-stage triple-negative breast cancer following neoadjuvant therapy

V. Karantza, A. Haiderali, P. Fasching, 2022, Annals of Oncology.

Overall survival with adjuvant atezolizumab after chemotherapy in resected stage II-IIIA non-small cell lung cancer (IMpower010): a randomised, multicentre, open-label, phase 3 trial.

A. Chella, H. Wakelee, E. Felip, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

883TiP MOONSTONE/GOG-3032: A phase II, open-label, single-arm study to evaluate the efficacy and safety of niraparib + dostarlimab in patients with platinum-resistant ovarian cancer

B. Monk, A. Secord, R. Coleman, 2020 .